{
    "startDate": "2021-03-01",
    "endDate": "2021-11-30",
    "year": "2022",
    "quarter": "Q3",
    "symbol": "BZYR",
    "data": {
        "bs": [
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 1389
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapitalCommonStock",
                "unit": "usd",
                "value": 125541505
            },
            {
                "label": "Total stockholders' deficit",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 5350
            },
            {
                "label": "Total stockholders' deficit",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 5350
            },
            {
                "label": "Total assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 6739
            },
            {
                "label": "Total liabilities and stockholders' deficit",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 6739
            },
            {
                "label": "Prepaids",
                "concept": "PrepaidExpenseCurrent",
                "unit": "usd",
                "value": 974
            },
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 5765
            },
            {
                "label": "Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 shares issued and outstanding as of November 30, 2021 and February 28, 2021",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 131449
            },
            {
                "label": "Total current assets",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 6739
            },
            {
                "label": "Commitments and contingencies",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "CURRENT AND TOTAL LIABILITIES",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 1389
            },
            {
                "label": "Retained deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -125667604
            }
        ],
        "cf": [
            {
                "label": "Accrued liabilities",
                "concept": "IncreaseDecreaseInAccruedLiabilities",
                "unit": "usd",
                "value": -14287
            },
            {
                "label": "Contribution of capital",
                "concept": "ProceedsFromContributedCapital",
                "unit": "usd",
                "value": 272701
            },
            {
                "label": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 272701
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -805777
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -805777
            },
            {
                "label": "NET INCREASE IN CASH",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
                "unit": "usd",
                "value": 5704
            },
            {
                "label": "Prepaids",
                "concept": "IncreaseDecreaseInPrepaidExpense",
                "unit": "usd",
                "value": 80
            },
            {
                "label": "NET CASH USED BY OPERATING ACTIVITIES",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -266997
            },
            {
                "label": "Accounts payable",
                "concept": "IncreaseDecreaseInAccountsPayable",
                "unit": "usd",
                "value": -31123
            },
            {
                "label": "FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.",
                "concept": "bzyr:ClinicalTrialExpensesPaid",
                "unit": "usd",
                "value": 584270
            }
        ],
        "ic": [
            {
                "label": "Operating loss before other income",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -805777
            },
            {
                "label": "Weighted average number of common shares outstanding Diluted",
                "concept": "WeightedAverageNumberOfDilutedSharesOutstanding",
                "unit": "shares",
                "value": 131448444
            },
            {
                "label": "Loss before provision for income tax",
                "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
                "unit": "usd",
                "value": -805777
            },
            {
                "label": "Loss per common share Diluted",
                "concept": "EarningsPerShareDiluted",
                "unit": "usd/shares",
                "value": -0.01
            },
            {
                "label": "Weighted average number of common shares outstanding Basic",
                "concept": "WeightedAverageNumberOfSharesOutstandingBasic",
                "unit": "shares",
                "value": 131448444
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 173302
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 632475
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -805777
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -805777
            },
            {
                "label": "Loss per common share Basic",
                "concept": "EarningsPerShareBasic",
                "unit": "usd/shares",
                "value": -0.01
            },
            {
                "label": "Total operating expenses",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 805777
            },
            {
                "label": "Provision for income tax",
                "concept": "OtherNoncashIncomeTaxExpense",
                "unit": "usd",
                "value": "N/A"
            }
        ]
    }
}